Introduction:Sickle cell disease (SCD) is a group of inherited diseases characterised by the presence of haemoglobin S (Hb S), either by homozygosity for the sickle mutation (Hb SS) or by mixed heterozygosity with another beta-globin variant (e.g. sickle beta thalassaemia, Hb SC disease). It is one of the most common haemoglobinopathies, especially in Middle Eastern countries. The hallmarks of SCD are recurrent vaso-occlusive crises and haemolytic anaemia. Vaso-occlusive crises manifest as acute pain crises, acute chest syndrome and priapism - they are mainly caused by obstructions of the microcirculation and lead to tissue hypoxia and severe pain.[1][2][3]Priapism is defined as a persistent erection of the penis that is not associated with sexual interest or desire. It can occur with low flow (ischaemic, vaso-occlusive) or high flow (non-ischaemic). In some series, it is estimated that 35 to 45 per cent of men with sickle cell disease (SCD) are affected by priapism. Ischaemic episodes lasting ≥4 hours (severe episodes) are of particular concern as they carry a high risk of permanent tissue damage from penile compartment syndrome. There is another vriant of ischaemic priapism, known as stuttering priapism, which is characterised by brief, recurrent episodes of transient, self-limited priapism.[4][5]Recent therapeutic advances have seen the approval of crizanlizumab, a monoclonal antibody targeting P-selectin, by the FDA in 2019 for reducing the frequency of SCD-related vaso-occlusive crises. Nonetheless, the efficacy of crizanlizumab in managing SCD-associated priapism has yet to be thoroughly investigated, underscoring a vital area for further clinical exploration [6].